Bispecific antigen binding molecules capable of specific binding to CD40 and to fap

US12145994B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Peter Bruenker · Hittnau, CH
• Alexander BUJOTZEK · Penzberg, DE
• Harald Duerr · Starnberg, DE
• Guy Georges · Habach, DE
• Christian Klein · Iffeldorf, DE
• Stephane Leclair · Gauting, DE
• Moritz RAPP · Schlieren, CH
• Eva Carina SUM · Schlieren, CH
• Christine TRUMPFHELLER · Schlieren, CH
• Pablo Umana · Wollerau, CH

Key dates

• Filing date: Feb 18, 2021
• Grant date: Nov 19, 2024
• Expiry date: Jun 22, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.